Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.

A novel class of drugs that target “BET” proteins may have broad utility for treating genetically diverse brain tumors.

The protein TIP-1 appears to be a novel prognostic marker for glioblastoma and may be a good therapeutic target for disrupting tumor-driven blood vessel development.

Investigators from Vanderbilt-Ingram Cancer Center and three other cancer centers have identified a link between a rare genetic variant and the risk of developing glioma.

Cells in the back of the developing brain can give rise to brain tumors, suggesting they may be a target for treatment.